Should Injectable Meloxicam Be Approved for Use in Cats?

Area of Science:

• Veterinary Pharmacology
• Animal Toxicology
• Drug Safety Evaluation

Background:

• Injectable meloxicam is frequently used in feline medicine.
• This NSAID has a known association with acute kidney injury (AKI) in cats.
• Concerns exist regarding the transparency of safety data in veterinary drug trials.

Purpose of the Study:

• To examine the omission of critical safety data from a published veterinary clinical trial.
• To question the approval process and industry influence on meloxicam prescribing.
• To highlight ethical considerations in pharmaceutical-sponsored veterinary research.

Main Methods:

• Review of a New Animal Drug Application (NADA) Freedom of Information Summary.
• Comparison of data submitted to the U.S. Food and Drug Administration (FDA) versus the published study.
• Analysis of financial sponsorship and its potential influence on veterinary organizations and practices.

Main Results:

• Data linking injectable meloxicam to AKI in cats were present in the FDA submission.
• These specific data regarding AKI were omitted from the published version of the clinical trial.
• The study was financially sponsored by the drug manufacturer, raising ethical questions.

Conclusions:

• The omission of AKI data from the published meloxicam trial warrants scrutiny.
• Pharmaceutical industry sponsorship may influence veterinary prescribing and policy.
• There is a need for greater transparency in veterinary drug trial reporting and ethical oversight.